In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mesoblast partners stem cell drugs exclusively with Cephalon

Executive Summary

Australian regenerative medicine firm Mesoblast Ltd. has licensed Cephalon Inc. exclusive global rights to therapeutics derived from adult mesenchymal precursor stem cells (MPCs) for degenerative neurological and cardiovascular diseases including congestive heart failure, acute myocardial infarction, angina, peripheral vascular disease/critical limb ischemia, Parkinson's, stroke, multiple sclerosis, Huntington's, and Alzheimer's. The deal will also include cell products that expand hematopoietic stem cell (bone marrow) transplants for blood cancer patients.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies